Coloplast A/S

BRSE:020259063 Stock Report

Market Cap: CHF 24.5b

Coloplast Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Kristian Villumsen

Chief executive officer

DKK 21.4m

Total compensation

CEO salary percentage54.2%
CEO tenure4yrs
CEO ownership0.04%
Management average tenure4.7yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kristian Villumsen's remuneration changed compared to Coloplast's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022DKK 21mDKK 12m

DKK 5b

Jun 30 2022n/an/a

DKK 5b

Mar 31 2022n/an/a

DKK 5b

Dec 31 2021n/an/a

DKK 5b

Sep 30 2021DKK 22mDKK 11m

DKK 5b

Jun 30 2021n/an/a

DKK 5b

Mar 31 2021n/an/a

DKK 4b

Dec 31 2020n/an/a

DKK 4b

Sep 30 2020DKK 20mDKK 11m

DKK 4b

Jun 30 2020n/an/a

DKK 4b

Mar 31 2020n/an/a

DKK 4b

Dec 31 2019n/an/a

DKK 4b

Sep 30 2019DKK 17mDKK 10m

DKK 4b

Jun 30 2019n/an/a

DKK 4b

Mar 31 2019n/an/a

DKK 4b

Dec 31 2018n/an/a

DKK 4b

Sep 30 2018DKK 11mDKK 6m

DKK 4b

Jun 30 2018n/an/a

DKK 4b

Mar 31 2018n/an/a

DKK 4b

Dec 31 2017n/an/a

DKK 4b

Sep 30 2017DKK 10mDKK 6m

DKK 4b

Jun 30 2017n/an/a

DKK 3b

Mar 31 2017n/an/a

DKK 3b

Dec 31 2016n/an/a

DKK 3b

Sep 30 2016DKK 10mDKK 6m

DKK 3b

Compensation vs Market: Kristian's total compensation ($USD3.06M) is below average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.

CEO

Kristian Villumsen (52 yo)

4yrs

Tenure

DKK 21,400,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leadership Team

NamePositionTenureCompensationOwnership
Kristian Villumsen
President & CEO4yrsDKK 21.40m0.043%
CHF 10.5m
Anders Lonning-Skovgaard
Executive VP & CFO8.4yrsDKK 10.80mno data
Allan Rasmussen
Executive Vice President of Global Operations8.4yrsDKK 9.60m0.00015%
CHF 36.8k
Nicolai Andersen
Executive Vice President of Innovationno dataDKK 9.00mno data
Paul Marcun
Executive Vice President of Growth3.9yrsDKK 11.00mno data
Thomas Barfod
Senior Controller & Employees Representative Directorno dataDKK 450.00k0.000030%
CHF 7.4k
Ellen Bjurgert
Vice President of Investor Relations6.2yrsno datano data
Dennis Kaysen
Director of Corporate Communicationsno datano datano data
Dorthe Ronnau
Senior Vice President of People & Cultureless than a yearno datano data
Alain Morvan
Senior Vice President of Sales Europe10.7yrsno datano data
Rasmus Møller
Senior Vice President of Wound & Skin Care2.3yrsno datano data
Manu Varma
Senior Vice President of Chronic Care - North America4.7yrsno datano data

4.7yrs

Average Tenure

53yo

Average Age

Experienced Management: 020259063's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Barfod
Senior Controller & Employees Representative Director16.9yrsDKK 450.00k0.000030%
CHF 7.4k
Carsten Hellmann
Independent Director5yrsDKK 690.00k0.0028%
CHF 694.2k
Lars Rasmussen
Chairman of the Board4yrsDKK 1.84m0.098%
CHF 24.0m
Niels Louis-Hansen
Deputy Chairman54.9yrsDKK 938.00k21.14%
CHF 5.2b
Marianne Wiinholt
Independent Director2yrsDKK 880.00k0.00024%
CHF 58.9k
Jette Nygaard-Andersen
Independent Director7yrsDKK 600.00kno data
Nikolaj Gundersen
Employees Representative Director4.9yrsDKK 450.00k0%
CHF 0
Roland Pedersen
Employees Representative Director4.9yrsDKK 450.00k0.00070%
CHF 171.7k
Annette Bruls
Independent Director1yrDKK 497.00kno data

4.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 020259063's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/14 02:37
End of Day Share Price 2022/09/16 00:00
Earnings2022/09/30
Annual Earnings2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 48 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Robert BateBarclays
Hassan Al-WakeelBarclays